Sept. 8 - Summit’s shaky case, Rapport’s stock surge and a startup drugging mitochondria
Rapport shares double on better-than-expected seizure drug data; A UK biotech takes aim at Parkinson’s, ALS by drugging mitochondria; Pfizer, BioNTech showcase new data supporting COVID booster
As your business grows, Fidelity is there to help with equity management solutions to meet your needs, from startup to IPO and beyond.
Put our experience to work.
The venture arms of Merck KGaA and Novartis are among the investors involved in raising $67 million for NRG Therapeutics, which aims to bring its first medicine into clinical testing next year.
The companies said their updated shot spurred an increase in neutralizing antibodies against currently circulating strains, answering calls for more corroborating evidence.
